Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ETV6 | P41212 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873090 | 0.89 | PLK4 (0.47) | KDRETV6FGFR1FLT1NTRK1 | |
| SCHEMBL5873162 | 0.89 | NTRK1 (0.55) | NTRK1 | |
| SCHEMBL5872877 | 0.88 | LRRK2 (0.46) | LRRK2MAPK1KDRETV6NTRK1 | |
| SCHEMBL5813034 | 0.87 | LRRK2 (0.55) | LRRK2FGFR1ITKARFLT1 | |
| SCHEMBL29602504 | 0.87 | LRRK2 (0.68) | LRRK2MAPK1KDRETV6FGFR1 | |
| SCHEMBL5872891 | 0.85 | FLT3 (0.46) | LRRK2KDRETV6FGFR1NTRK1 | |
| SCHEMBL5873038 | 0.84 | NTRK1 (0.40) | LRRK2MAPK1FGFR1FLT1NTRK1 | |
| SCHEMBL5872887 | 0.84 | ACVR1 (0.44) | FGFR1NTRK1 | |
| SCHEMBL5873134 | 0.83 | PIM1 (0.42) | FGFR1NTRK1PLK4FLT3 | |
| SCHEMBL5872943 | 0.81 | ALDH1A1 (0.43) | LRRK2FGFR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | LRRK2 2922/4885MAPK1 2837/4885KDR 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.